1) Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observa-tions and clinical implications. Circulation 1990 ; 81: 1161.
2) Rouleau JL, de Champlain J, Klein M, et al. Activa-tion of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993 ; 22 : 390.
3) Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myo- cardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 ; 360 : 752.
4) Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor an-tagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarc-tion. Circulation 2003: 107 :2559.
5) Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 ; 348: 1309.